MXPA05003273A - Procedimiento para preparar inhibidores de quinazolina rho-cinasa e intermediarios de los mismos. - Google Patents
Procedimiento para preparar inhibidores de quinazolina rho-cinasa e intermediarios de los mismos.Info
- Publication number
- MXPA05003273A MXPA05003273A MXPA05003273A MXPA05003273A MXPA05003273A MX PA05003273 A MXPA05003273 A MX PA05003273A MX PA05003273 A MXPA05003273 A MX PA05003273A MX PA05003273 A MXPA05003273 A MX PA05003273A MX PA05003273 A MXPA05003273 A MX PA05003273A
- Authority
- MX
- Mexico
- Prior art keywords
- rho
- kinase inhibitors
- intermediates
- preparing quinazoline
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/93—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invencion se relaciona con metodos para producir compuestos de quinazolina (I) y derivados de los mismos los cuales son utiles como inhibidores de Rho-cinasa o intermediarios de los mismos (3) los inhibidores de Rho-cinasa son utiles para inhibir el crecimiento de tumores, tratar disfuncion erectil y tratar otras indicaciones mediadas por rho-cinasa, por ejemplo cardiopatia coronaria.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/252,369 US7645878B2 (en) | 2002-03-22 | 2002-09-24 | Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof |
PCT/US2003/029538 WO2004029045A2 (en) | 2002-09-24 | 2003-09-24 | Process for preparing quinazoline rho-kinase inhibitors and intermediates thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05003273A true MXPA05003273A (es) | 2005-10-18 |
Family
ID=29549713
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05003273A MXPA05003273A (es) | 2002-09-24 | 2003-09-24 | Procedimiento para preparar inhibidores de quinazolina rho-cinasa e intermediarios de los mismos. |
Country Status (7)
Country | Link |
---|---|
US (2) | US7645878B2 (es) |
EP (2) | EP1542992A2 (es) |
JP (2) | JP4624791B2 (es) |
AU (1) | AU2003270785A1 (es) |
CA (2) | CA2751086A1 (es) |
MX (1) | MXPA05003273A (es) |
WO (1) | WO2004029045A2 (es) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4860474B2 (ja) * | 2003-05-20 | 2012-01-25 | バイエル、ファーマシューテイカルズ、コーポレイション | Pdgfrによって仲介される病気のためのジアリール尿素 |
DK1663978T3 (da) * | 2003-07-23 | 2008-04-07 | Bayer Pharmaceuticals Corp | Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser |
US20080146562A1 (en) * | 2003-08-08 | 2008-06-19 | Ulysses Pharmaceutical Products Inc., | Halogenated quinazolinyl nitrofurans as antibacterial agents |
CA2534405A1 (en) * | 2003-08-08 | 2005-02-17 | Ulysses Pharmaceutical Products Inc. | Halogenated quinazolinyl nitrofurans as antibacterial agents |
CA2553433A1 (en) | 2004-01-23 | 2005-08-11 | Amgen Inc. | Quinoline quinazoline pyridine and pyrimidine compounds and their use in the treatment of inflammation angiogenesis and cancer |
CN1933839A (zh) | 2004-01-23 | 2007-03-21 | 安进公司 | 化合物和使用方法 |
DK1746999T3 (da) | 2004-05-06 | 2012-01-23 | Warner Lambert Co | 4-phenylamino-quinazolin-6-yl-amider |
WO2005120509A1 (en) * | 2004-06-04 | 2005-12-22 | Amphora Discovery Corporation | Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
US7652009B2 (en) | 2004-11-30 | 2010-01-26 | Amgem Inc. | Substituted heterocycles and methods of use |
CR9465A (es) | 2005-03-25 | 2008-06-19 | Surface Logix Inc | Compuestos mejorados farmacocineticamente |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
EP2068878B1 (en) * | 2006-09-20 | 2019-04-10 | Aerie Pharmaceuticals, Inc. | Rho kinase inhibitors |
CA2700988A1 (en) * | 2006-09-27 | 2008-05-08 | Surface Logix, Inc. | Rho kinase inhibitors |
US7851623B2 (en) * | 2006-11-02 | 2010-12-14 | Astrazeneca Ab | Chemical process |
US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
JP5343082B2 (ja) * | 2007-10-29 | 2013-11-13 | アムジエン・インコーポレーテツド | ベンゾモルホリン誘導体および使用方法 |
US8455514B2 (en) | 2008-01-17 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-and 7-amino isoquinoline compounds and methods for making and using the same |
US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
CA2929545C (en) | 2009-05-01 | 2019-04-09 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
ES2750598T3 (es) | 2009-09-03 | 2020-03-26 | Bristol Myers Squibb Co | Quinazolinas como inhibidores de los canales iónicos de potasio |
DK2638149T3 (da) | 2010-11-12 | 2019-08-12 | Univ Georgetown | Immortalisering af epitelceller og fremgangsmåder til anvendelse |
CN103857288B (zh) | 2011-03-04 | 2016-09-21 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为激酶抑制剂的氨基-喹啉 |
TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
AR092529A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
AR094707A1 (es) | 2013-02-21 | 2015-08-19 | Glaxosmithkline Ip Dev Ltd | Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2 |
CN109528721B (zh) | 2013-03-15 | 2021-10-01 | 爱瑞制药公司 | 联合治疗 |
US9629851B2 (en) | 2013-09-20 | 2017-04-25 | Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis | ROCK in combination with MAPK pathway |
CA2953524A1 (en) | 2014-06-27 | 2015-12-30 | The Regents Of The University Of California | Cultured mammalian limbal stem cells, methods for generating the same, and uses thereof |
CN107636149A (zh) | 2015-04-03 | 2018-01-26 | 普罗帕格尼克斯公司 | 上皮细胞的离体增殖 |
US10100285B2 (en) | 2015-04-03 | 2018-10-16 | Propagenix Inc. | Ex vivo proliferation of epithelial cells |
CA2998372A1 (en) | 2015-09-11 | 2017-03-16 | Chengkang ZHANG | Ex vivo proliferation of epithelial cells |
JP6832946B2 (ja) | 2015-11-17 | 2021-02-24 | アエリエ ファーマシューティカルズ インコーポレイテッド | キナーゼ阻害剤およびその中間体の調製方法 |
US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
JP6907319B2 (ja) | 2016-08-31 | 2021-07-21 | アエリエ ファーマシューティカルズ インコーポレイテッド | 眼科用組成物 |
CN108239071B (zh) * | 2016-12-27 | 2020-12-04 | 沈阳药科大学 | 酰胺及硫代酰胺类衍生物及其制备方法和应用 |
AU2018243687C1 (en) | 2017-03-31 | 2020-12-24 | Alcon Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
WO2020041065A1 (en) | 2018-08-20 | 2020-02-27 | Propagenix Inc. | Epithelial cell spheroids |
CA3110661A1 (en) | 2018-08-29 | 2020-03-05 | University Of Massachusetts | Inhibition of protein kinases to treat friedreich ataxia |
WO2020056345A1 (en) | 2018-09-14 | 2020-03-19 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
UY38427A (es) | 2018-10-26 | 2020-05-29 | Novartis Ag | Métodos y composiciones para terapia con células oculares |
WO2020214537A1 (en) * | 2019-04-15 | 2020-10-22 | Tosk, Inc. | Modulators of ras gtpase |
WO2021220132A1 (en) | 2020-04-27 | 2021-11-04 | Novartis Ag | Methods and compositions for ocular cell therapy |
CA3235384A1 (en) | 2021-10-18 | 2023-04-27 | Takahiro Ochiya | Compositions and methods of use thereof for treating liver fibrosis |
AU2022369459A1 (en) | 2021-10-22 | 2024-05-30 | Evia Life Sciences Inc. | Methods for making extracellular vesicles, and compositions and methods of use thereof |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3583287D1 (de) | 1984-12-27 | 1991-07-25 | Asahi Chemical Ind | Substituierte isochinolinsulfonyl-verbindungen. |
IL78649A0 (en) | 1985-05-30 | 1986-08-31 | Basf Ag | Benzoate derivatives,their preparation and their use as pesticides |
US5714493A (en) * | 1991-05-10 | 1998-02-03 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
GB9301192D0 (en) | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
EP0912559B1 (en) | 1996-07-13 | 2002-11-06 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
CZ301044B6 (cs) | 1996-08-12 | 2009-10-21 | Mitsubishi Tanabe Pharma | Léciva obsahující amidové deriváty inhibující Rho kinázu |
US6103765A (en) | 1997-07-09 | 2000-08-15 | Androsolutions, Inc. | Methods for treating male erectile dysfunction |
US6124461A (en) | 1998-05-26 | 2000-09-26 | Saint Louis University, Health Services Center, Research Administration | Compounds, compositions, and methods for treating erectile dysfunction |
CN1293878C (zh) | 1998-08-17 | 2007-01-10 | 千寿制药株式会社 | 眼睛疲劳或假性近视预防或治疗剂 |
AU5682799A (en) | 1998-08-21 | 2000-03-14 | Parker Hughes Institute | Quinazoline derivatives |
US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
US6080747A (en) | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
DE60036540T2 (de) | 1999-03-25 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp. | Rho-kinase-inhibitoren für die vorbeugung oder behandlung von interstitieller pneumonie und pulmonaler fibrose |
CA2369552A1 (en) | 1999-04-22 | 2000-11-02 | Hisashi Kai | Agent for prophylaxis and treatment of angiostenosis |
ES2365692T3 (es) | 1999-04-27 | 2011-10-10 | Mitsubishi Tanabe Pharma Corporation | Medicamento para la prevención o tratamiento terapéutico de enfermedades hepáticas. |
AU5250400A (en) | 1999-06-18 | 2001-01-09 | Mitsubishi Pharma Corporation | Osteogenesis promoters |
MXPA03002410A (es) | 2000-09-20 | 2003-06-19 | Merck Patent Gmbh | 4-amino-quinazolinas. |
CA2425779C (en) | 2000-10-12 | 2013-08-06 | University Of Rochester | Compositions that inhibit proliferation of cancer cells |
AU2002246924A1 (en) | 2001-01-05 | 2002-07-16 | The Medical College Of Georgia Research Institute, Inc. | Treatment of erectile dysfunction with rho-kinase inhibitors |
PE20021011A1 (es) * | 2001-03-23 | 2003-02-01 | Bayer Corp | Derivados quinazolinicos como inhibidores de la rho-quinasa |
ATE353889T1 (de) * | 2001-03-23 | 2007-03-15 | Bayer Pharmaceuticals Corp | Rho-kinase inhibitoren |
-
2002
- 2002-09-24 US US10/252,369 patent/US7645878B2/en not_active Expired - Fee Related
-
2003
- 2003-09-24 WO PCT/US2003/029538 patent/WO2004029045A2/en active Application Filing
- 2003-09-24 EP EP03752497A patent/EP1542992A2/en not_active Withdrawn
- 2003-09-24 CA CA2751086A patent/CA2751086A1/en not_active Abandoned
- 2003-09-24 MX MXPA05003273A patent/MXPA05003273A/es unknown
- 2003-09-24 AU AU2003270785A patent/AU2003270785A1/en not_active Abandoned
- 2003-09-24 CA CA2507381A patent/CA2507381C/en not_active Expired - Fee Related
- 2003-09-24 JP JP2004540124A patent/JP4624791B2/ja not_active Expired - Fee Related
- 2003-09-24 EP EP08103780A patent/EP1953152A1/en not_active Withdrawn
-
2009
- 2009-11-17 US US12/619,884 patent/US20100125139A1/en not_active Abandoned
-
2010
- 2010-09-28 JP JP2010216425A patent/JP2011021027A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2006508068A (ja) | 2006-03-09 |
CA2507381C (en) | 2012-07-10 |
US20100125139A1 (en) | 2010-05-20 |
JP4624791B2 (ja) | 2011-02-02 |
EP1953152A1 (en) | 2008-08-06 |
JP2011021027A (ja) | 2011-02-03 |
CA2751086A1 (en) | 2004-04-08 |
AU2003270785A1 (en) | 2004-04-19 |
WO2004029045A2 (en) | 2004-04-08 |
US7645878B2 (en) | 2010-01-12 |
WO2004029045A3 (en) | 2004-07-22 |
CA2507381A1 (en) | 2004-04-08 |
EP1542992A2 (en) | 2005-06-22 |
US20030220357A1 (en) | 2003-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA05003273A (es) | Procedimiento para preparar inhibidores de quinazolina rho-cinasa e intermediarios de los mismos. | |
MY134783A (en) | Rho-kinase inhibitors | |
MY142915A (en) | Rho-kinase inhibitors | |
DE60318177D1 (de) | Rho-kinase inhibitoren | |
WO2005003101A3 (en) | Pyrazine and pyridine derivatives as rho kinase inhibitors | |
YU84603A (sh) | Novi inhibitori tirozin kinaze | |
EP2402325A3 (en) | Hydroxylated and methoxylated cyclopenta[d]pyrimidines as AKT protein kinase inhibitors | |
ATE374609T1 (de) | Synthese von 4-aminothalidomid enantiomeren | |
HK1069169A1 (en) | Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors | |
NO20030895D0 (no) | Ny anvendelse av dipeptidyl peptidase IV inhibitorer | |
ZA200406813B (en) | Glytaminyl based DPIV inhibitors | |
HK1096673A1 (en) | Compositions useful as inhibitors of protein kinases | |
DE602004015810D1 (de) | Substituierte isochinolinderivate und anwendungsverfahren | |
RS60503A (en) | Substituted alkylamine derivatives and methods of use | |
DE602004024900D1 (de) | Substituierte 2,3-dihydro-1h-isoindol-1-one derivate und anwendungsverfahren | |
TW200633977A (en) | Novel process for the manufacture of 3-pyrrolidin-2-yl-propionic acid derivatives | |
IS5588A (is) | Æxliseyðandi miðlar | |
MXPA03004347A (es) | Nuevos derivados de imidazol, metodo de produccion y uso de los mismos. | |
SI1606288T1 (sl) | Derivati benzensulfonamida, postopek za njihovo pripravo in njihova uporaba za zdravljenje bolečine | |
MXPA04000531A (es) | Acilsemicarbazidas como inhibidores de cinasa dependiente de ciclina utiles como agentes anti-cancer y anti-proliferativos. | |
BR0318521A (pt) | arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados | |
ATE372114T1 (de) | Verfahren zur erhöhung des testosteronspiegels | |
ATE386734T1 (de) | Verfahren zur herstellung von (4-hydroxy-6-oxo- tetrahydropyran-2-yl) acetonitril und dessen derivaten | |
EP1400522A4 (en) | NEW COMPOUNDS FOR THE TREATMENT OF IMPUSE | |
DE60335980D1 (de) | Verfahren zur herstellung von synthetischen derivaten von dibenzylbutyrolacton-lignanen mit antichagas eigenschaften |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |